Lincoln National Corp’s Atossa Therapeutics ATOS Stock Holding History

Lincoln National Corp’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-689	Closed	-$7.5K	–	1023
2023 Q1	$7.5K	Hold	689	–	–	﹤0.01%	984
2022 Q4	$5.46K	Hold	689	–	–	﹤0.01%	928
2022 Q3	$9K	Hold	689	–	–	﹤0.01%	867
2022 Q2	$11K	Hold	689	–	–	﹤0.01%	857
2022 Q1	$13K	Hold	689	–	–	﹤0.01%	906
2021 Q4	$17K	Hold	689	–	–	﹤0.01%	888
2021 Q3	$34K	Hold	689	–	–	﹤0.01%	857
2021 Q2	$65K	Sell	689 -178	-21%	-$9.42K	﹤0.01%	847
2021 Q1	$28K	Buy	+867	New	+$31.7K	﹤0.01%	799

Other funds holding ATOS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Lincoln National Corp's ATOS Position: Q2 2023 in Review

Lincoln National Corp sold out of Atossa Therapeutics (ATOS) in Q2 2023, closing a stake of 689 shares — an estimated $7.5K sold.

Lincoln National Corp first reported a position in ATOS in Q1 2021 and held it in 9 quarters. The position peaked at $65K in Q2 2021. 52 funds tracked by Wall St. Rank hold ATOS as of Q2 2023.

Lincoln National Corp reported no remaining Atossa Therapeutics position as of Q2 2023 after selling out during the quarter.
Lincoln National Corp sold 689 Atossa Therapeutics shares in Q2 2023, an estimated $7.5K.
Lincoln National Corp first reported a position in Atossa Therapeutics in Q1 2021 and held it in 9 quarters.
Lincoln National Corp's Atossa Therapeutics position peaked at $65K in Q2 2021.
52 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2023.

Based on Lincoln National Corp's 13F filing for Q2 2023, filed 7 Aug 2023.